Long-term Outcomes

Single-Infusion CRISPR Therapy Lowers LDL and Triglycerides in First Human Trial

By switching off ANGPTL3 in the liver, CTX310 produced rapid lipid reductions in 15 adults, with only mild short-term reactions reported.